The MDR1 gene encoding the multidrug pump Pglycoprotein is transcriptionally activated in response to diverse extracellular stimuli, including the tumor promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). However, the signal transduction pathway responsible is unknown. Downstream of protein kinase C (PKC), the eects of TPA are often mediated by the Raf-1/MEK/ERK mitogen-activated protein kinase (MAPK) cascade, and Raf-1 has been implicated in MDR1 induction by serum and mitogens. Therefore, we examined the potential role of MAPK activation in TPA-mediated MDR1 induction in human leukemia K562 cells. MDR1 mRNA expression was signi®cantly increased by TPA in the concentration range of 4 ± 100 nM, with a maximal response 5 ± 10 h after TPA addition. TPA-mediated MDR1 induction was inhibited by several PKC inhibitors including staurosporine, H7 and calphostin C. TPA stimulated the subcellular translocation of PKCa from the cytosol to the membrane and nucleus but did not aect other PKC isozymes. TPA also activated the Raf1/MEK/ERK cascade and activated another MAPK member, p38, but not JNK. In order to determine the potential role of MAPKs in MDR1 induction by TPA, speci®c inhibitors were utilized. The MEK inhibitor PD 098059, as well as the PKC inhibitors, completely blocked TPA-mediated ERK activation. However, under identical conditions, MDR1 induction by TPA was completely unaected by PD 098059. Furthermore, SB 202190, which eectively inhibited TPA-mediated p38 activation, failed to inhibit TPA-induced MDR1 mRNA expression. These data demonstrate that MDR1 induction by TPA occurs via a PKC-dependent mechanism that operates independently of ERK, p38 or JNK pathways, and thus have important implications for understanding the mechanisms of MDR1 induction by extracellular stimuli.
Introduction
A major factor in broad spectrum anticancer drug resistance is the overexpression of dierent types of multidrug transporters of the ATP binding cassette family including Pglycoprotein (Germann, 1996; Germann and Chambers, 1998) , multidrug resistance protein (Loe et al., 1996) , lung-resistance protein (Izquierdo et al., 1996) , and most likely others to be discovered. In normal human tissues, P-glycoprotein, the product of the MDR1 gene, is expressed at highest levels in the adrenal glands, colon, liver and kidney, and at lower levels in the capillary endothelial cells of the testis and brain as well as in hematopoietic stem cells (Gottesman et al., 1991a) . MDR1 expression is frequently observed in human tumors (Gottesman et al., 1991b) . Highest expression occurs in cancers derived from tissues which normally express the gene such as colon, liver, and kidney, and this may account in part for the intrinsic resistance to chemotherapy observed in these tumor types. For certain cancer types such as the leukemias, lymphomas, neuroblastomas, breast and ovarian cancers, MDR1 expression is low before chemotherapy but frequently increased after chemotherapy (Gottesman et al., 1991b) . In this acquired resistance, increased MDR1 expression is often predictive of poor response to chemotherapy. Finally, increased MDR1 expression has been observed in untreated human cancers, and gene activation in these cases may be one manifestation of the complex genetic changes occurring during malignant transformation and tumor progression (Bradley and Ling, 1994; Chin et al., 1993) .
In cultured cell lines, P-glycoprotein overexpression is usually the result of gene ampli®cation, whereas in patient tumors gene ampli®cation has not been observed and overexpression results from transcriptional activation and/or posttranscriptional events (Rischin and Ling, 1993) . Therefore, much eort has been directed toward understanding the mechanisms of transcriptional regulation of the MDR1 gene (Cornwell, 1996; Ince and Scotto, 1997) . MDR1 gene activation can occur in response to a diverse spectrum of stimuli including dierentiation factors, developmental signals, and environmental stress such as heat shock, UV irradiation, carcinogens, and chemotherapeutic drugs. Consistent with these ®ndings, the promoter region and intron 1 of MDR1 show a high degree of complexity with numerous putative regulatory sites (Thorgeirsson et al., 1994; Glazer and Rohl, 1994) . Several protein binding regions upstream of the initiation site have been shown to transactivate the MDR1 promoter including those for NF-Y, NF-IL6, SP1 and EGR1 proteins (reviewed in Cornwell, 1996; Ince and Scotto, 1997) .
Among the most potent inducers of MDR1 expression are agents that activate protein kinase C (PKC). The tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) or diacylglycerol (DAG) were shown to increase MDR1 mRNA and P-glycoprotein expression in normal human lymphocytes and in several cancer cell lines derived from leukemias as well as solid tumors, and staurosporine inhibited this eect, suggesting a PKC-mediated pathway (Chaudhary and Roninson, 1992) . TPA or DAG were particularly strong inducers of MDR1 mRNA in human leukemia K562 and H9 cell lines (Chaudhary and Roninson, 1992) . McCoy et al. (1995) characterized the cis-acting sequences and trans-acting factors regulating TPA-mediated MDR1 expression in K562 cells and an early growth response-1 (EGR1) element in the MDR1 promoter was implicated. Importantly however, the signaling pathway responsible for TPAmediated MDR1 gene activation has not been determined. PKC is composed of a large family of isozymes many of which are TPA-responsive (Liu, 1996) , but the speci®c isozymes involved in TPAmediated MDR1 induction have not been identi®ed. PKC can in¯uence transcriptional activity by functioning directly in the nucleus or indirectly by triggering a nucleus-directed signaling cascade (Buchner, 1995) . For example, phorbol esters and other mitogenic stimuli acting via PKC often activate the mitogen-activated protein kinase (MAPK) module composed of Raf-1 kinase, mitogen-activated/extracellular response kinase kinase (MEK) and extracellular response kinase (ERK) (Cobb and Goldsmith, 1995) , and direct phosphorylation and activation of Raf-1 by PKCa has been reported (Kolch et al., 1993) . Transfection studies with reporter genes have implicated Raf-1 kinase in the transcriptional regulation of the MDR1 gene following serum and mitogenic stimulation of NIH3T3 cells (Cornwell and Smith, 1993) . In addition, increased expression of MDR1 in rat liver epithelial cells has been reported after transformation with v-raf kinase (Burt et al., 1988) , and stimulation of human MDR1 promoter activity by the c-Ha-Ras-1 oncogene has been observed (Chin et al., 1992) . Thus, several upstream components of the MAPK cascade have been implicated in MDR1 induction by serum and mitogens, but a requirement for MAPK activation has not been demonstrated. Making use of recently developed MAPK inhibitors, we show in this paper that MDR1 induction by TPA occurs independently of ERK, p38 or c-Jun NH 2 -terminal kinase (JNK) signaling pathways.
Results

Induction of MDR1 by TPA and inhibition by PKC inhibitors
Previous studies have indicated that treatment of K562 cells with TPA induces expression of the MDR1 gene at both the mRNA and protein levels and occurs mainly through a transcriptional mechanism (Chaudhary and Roninson, 1992; McCoy et al., 1995) . To provide a foundation to study the signaling pathway responsible, we initially sought to reproduce and extend these earlier ®ndings. K562 cells were treated with TPA, and MDR1 mRNA was analysed by reverse transcriptase-polymerase chain reaction (RT ± PCR), using a modi®cation of a quantitative assay as described in`Materials and methods.' As shown in Figure 1A , a low level of MDR1 mRNA was detected in control cells, and treatment with 32 nM TPA signi®cantly increased expression, with a near maximum response occuring 5 ± 10 h after addition of TPA. Exposure of cells to dierent concentrations of TPA (4 ± 100 nM) for 16 h showed that a maximum response was observed at the lowest TPA concentration tested ( Figure 1B) . b 2 -microglobulin mRNA levels measured as a control were relatively unaected by TPA. Phosphorimage analysis of the results shown in Figure  1 , as well as results from two repeats of this Figure 1 Time-and dose-dependencies of MDR1 induction by TPA and eects of PKC inhibitors. K562 cells were treated with 32 nM TPA for the indicated times (A) or for 16 h at the indicated concentrations of TPA (B). In (C), K562 cells were treated with vehicle alone or 32 nM TPA for 16 h, either in the absense or presence of staurosporine (ST), at several indicated concentrations. In (D), cells were treated with vehicle or 32 nM TPA for 16 h, either in the absense or presence of 100 mM H7 or 1 mM calphostin C (CalC), as indicated. The kinase inhibitors were added 30 min prior to TPA. Following treatments, RNA was prepared and MDR1-speci®c (167 base pairs, bp) or b 2 -microglobulin (b 2 M)-speci®c (120 bp) PCR products were ampli®ed using 32 P-labeled primers, and analysed by gel electrophoresis and autoradiography, as described in Materials and methods. Molecular size standards of 126 bp and 179 bp are indicated experiment, indicated that TPA maximally increased MDR1-speci®c PCR products 16+3 fold (mean+s.d., n=12).
To demonstrate that MDR1 induction by TPA required PKC activation, several kinase inhibitors were utilized including staurosporine (IC 50 for PKC=2.7 nM; Tamaoki et al., 1986) , H7 (IC 50 for PKC=6 mM; Kawamoto and Hidaka, 1984) and calphostin C (IC 50 for PKC=50 nM; Kobayashi et al., 1989) . Staurosporine was very eective at 1 mM, completely inhibiting TPA-induced MDR1 expression, and was partially eective at 100 nM (50% inhibition, as determined by phosphorimage analysis), but was ineective at lower concentrations ( Figure 1C ). H7 at 100 mM was also an eective inhibitor of TPAmediated MDR1 induction ( Figure 1D ). However, because both staurosporine and H7 can inhibit other kinase at high concentrations, we also tested calphostin C which is selective for PKC (Kobayashi et al., 1989) . Calphostin C also very eectively inhibited TPAmediated MDR1 induction ( Figure 1D ).
Translocation of PKCa in response to TPA
TPA-responsive members of the PKC family are likely candidates for initiating the signaling pathway of MDR1 induction by TPA, but they have not previously been investigated in this context. We therefore examined the expression and subcellular distribution of PKC isozymes in control and TPAtreated K562 cells by immunoblotting with isozymespeci®c antibodies. Consistent with earlier ®ndings (Murray et al., 1993; Zheng et al., 1994) , we detected conventional (calcium-and TPA/DAG-dependent) PKC subtypes PKCa and PKCb, and the atypical (calcium-and TPA/DAG-independent) PKCz subtype, as the major isozymes present, whereas novel isozymes PKCd and PKCe were not detected. PKCb was present mainly in the particulate fraction, and PKCz was present in both cytosolic and particulate fractions, and their subcellular localizations were unaected by TPA treatment of the cells (data not shown). In contrast, PKCa, which was mainly present in the cytosol of unstimulated cells, translocated from the cytosol to the particulate fraction in response to TPA (Figure 2 ). The concentration-dependence of TPA-induced PKCa translocation, with a treatment time of 30 min, indicated that signi®cant translocation of the enzyme occurred at 4 nM TPA, with a near maximal response in the range 32 ± 200 nM TPA ( Figure 2A ). The timecourse of TPA-induced PKCa translocation at an optimal concentration of 32 nM indicated a very rapid Figure 2 PKCa translocation in response to TPA. K562 cells were treated for 30 min with the indicated concentrations of TPA (A), or with 32 nM TPA for the indicated times (B). Cytosolic and particulate fractions were prepared and 16 mg protein/lane was applied to SDS ± PAGE and PKCa detected by immunoblotting. RB, rat brain PKC. In (C), cells were treated with 32 nM TPA for the indicated times, nuclear extracts were prepared as described in Materials and methods, and 25 mg protein/lane was applied to SDS ± PAGE and PKCa detected by immunoblotting. Molecular mass standards (in kDa) are indicated on the right response, occurring within 5 min of addition of TPA to the cells ( Figure 2B ). In addition to membrane translocation, TPA also stimulated rapid nuclear translocation of PKCa ( Figure 2C ). Because subcellular redistribution is a hallmark of PKC activation, these results suggest that PKCa may play a major role in mediating the eects of TPA in these cells.
Activation of Raf-1 and ERK in response to TPA As discussed above, the MAPK pathway has been implicated in MDR1 induction by serum and mitogens, and this signaling cascade can be initiated by the direct phosphorylation of Raf-1 on Ser499 by PKCa resulting in Raf-1 activation (Kolch et al., 1993) . We therefore evaluated Raf-1 activation. Figure 3 shows that in control K562 cells, Raf-1 immunoreactivity is detectable mainly in the cytosolic fraction and to a lesser degree in the particulate fraction. Treatment of cells for 30 min with TPA in the concentration range of 4 ± 200 nM promoted Raf-1 activation ( Figure 3A ), evident as a characteristic retardation in electrophoretic mobility following phosphorylation-induced activation (Daum et al., 1994) . Raf-1 activation occurred rapidly within 5 min of addition of TPA, and was sustained ( Figure 3B ). It is evident that the time-and dosedependencies of Raf-1 activation by TPA closely parallel those of PKCa membrane translocation (Figure 2) , supporting a mechanism whereby Raf-1 activation is directly mediated by PKCa.
We next examined activation of the MAPK cascade at the level of p44 MAPK (ERK1) and p42 MAPK (ERK2) after TPA treatment of K562 cells. Whole cell extracts were prepared and subject to immunoblot analysis with an antibody recognizing only the phosphorylated, activated forms of ERK1/2. Phospho-ERK1/2 immunoreactivity was low in control cells but was signi®cantly increased after 30 min TPA treatment, with phosphorylated forms of both ERK1 and ERK2 detectable ( Figure 4A ). The kinetics of ERK activation by 32 nM TPA were examined ( Figure 4B ). The response was rapid, with signi®cant enzyme activation . Whole cell extracts were prepared and analysed for the presence of phosphorylated ERK1/ 2 (P-ERK1/2) by SDS ± PAGE (80 mg protein/lane) and immunoblotting with phospho-speci®c antibody, as described in Materials and methods. ERK activity was also evaluated by an immunocomplex assay with myelin basic protein (MBP) as substrate, an autoradiograph of which is shown (C). Cells were either untreated (Cont) or treated with 32 nM TPA for 30 min (TPA) and 400 mg of cell extract subject to immunoprecipitation. Molecular mass standards (in kDa) are indicated after 5 min treatment with TPA, and the response was sustained, with activated enzyme present following prolonged exposure of cells to TPA up to 4 h ( Figure  4B ) or up to 16 h. To con®rm these ®ndings with an independent method, ERK activity was measured directly by an immunocomplex assay with myelin basic protein as substrate, and signi®cantly increased enzyme activity was observed after TPA treatment of the cells ( Figure 4C ).
Inhibition of TPA-induced ERK activation by PD 098059 or staurosporine
The results presented above show that TPA is a potent inducer of MDR1 mRNA and, at similar concentrations, promotes membrane association of PKCa and sustained activation of the Raf-1/MEK/ERK MAPK cascade, in K562 cells. To determine whether MDR1 induction by TPA required MAPK activation, the MEK inhibitor PD 098059 (IC 50 of 7 ± 10 mM) was employed (Dudley et al., 1995) . To demonstrate the ecacy of PD 098059 in this system, cells were stimulated with 32 nM TPA for dierent times from 30 min to 16 h, in the absence or presence of 100 mM PD 098059 added 30 min prior to TPA. Cell extracts were prepared and examined for the presence of activated ERK1/2 by immunoblotting with the phospho-speci®c antibody. PD 098059 was found to be extremely eective, completely inhibiting TPAinduced ERK1/2 activation ( Figure 5 ). Staurosporine also inhibited TPA-mediated activation of ERK1/2 ( Figure 5) , and H7 and calphostin C were similarly eective (data not shown). The same results have been obtained in three repeats of this experiment, and indicate that ERK activation requires both PKC and MEK activations. Immunoblotting of the same extracts with a phosphorylation-independent anti-ERK1/2 antibody indicated that total ERK1/2 protein levels were unaected under the experimental conditions ( Figure 5 , lower panel).
TPA-induced MDR1 expression is unaected by PD 098059
We next examined the eects of PD 098059 on TPAinduced MDR1 expression. For comparison, we also used staurosporine, which was shown earlier to block TPA-mediated MDR1 induction ( Figure 1C ). K562 cells were treated with vehicle or 32 nM TPA for 16 h in the absence or presence of either 100 mM PD 098059 or 1 mM staurosporine, with the inhibitors added 30 min prior to TPA. These conditions were thus identical to those described for Figure 5 . MDR1 mRNA and b 2 -microglobulin mRNA levels were determined by PCR (Figure 6 ). In contrast to staurosporine, PD 098059 failed to inhibit TPAinduced MDR1 mRNA expression. This was con®rmed by phosphorimage analysis which showed that the ratios of MDR1-speci®c PCR product to that of b 2 -microglobulin were, in arbitrary units, 1.08 in lane 2 (TPA only) versus 1.05 in lane 3 (TPA plus PD 098059). b 2 -microglobulin levels were essentially unaected by the dierent treatments as indicated by visual inspection and con®rmed by phosphorimage analysis. Identical results to those shown in Figure 6 have been obtained in several repeats of this experiment (n=6).
MDR1 induction by TPA does not involve p38 or JNK
Two other members of the MAPK family, p38 and JNK, were also examined as potential mediators of MDR1 induction by TPA. Although these MAPK subtypes are generally responsive to stress stimuli rather than mitogenic stimuli (Kyriakis and Avruch, 1996) , activation of p38 and JNK by TPA has been reported in certain cell types (e.g. Simon et al., 1998) . We ®rst investigated a possible role of p38, making use of an antibody speci®c for the phosphorylated, activated form of the enzyme. As shown in Figure  7A , TPA treatment of K562 cells resulted in a timedependent, transient p38 activation. In order to inhibit p38, we employed the speci®c inhibitor SB 202190 (IC 50 of 0.3 mM; Gallagher et al., 1997). First, we determined the ecacy of SB 202190, which inhibits the catalytic activity of p38 and also inhibits stimulus-induced phosphorylation at the Thr-Gly-Tyr activation motif (Frantz et al., 1998) . K562 cells were treated with vehicle or TPA, in the absence or presence of SB 202190, and cell extracts were made and subjected to immunoblotting with the phospho-p38 antibody. The results, shown in Figure 7B , demonstrated that SB Figure 5 Eect of inhibitors of PKC or MEK on ERK activation by TPA. K562 cells were treated with vehicle alone or 32 nM TPA for 16 h. PD 098059 (100 mM) or staurosporine (1 mM) were added 30 min prior to TPA as indicated. Whole cell extracts were analysed for the presence of phosphorylated ERK1/ 2 (P-ERK1/2) by immunoblotting as in Figure 4 . In the lower panel, the same extracts were subjected to immunoblotting with a phosphorylation-independent antibody to ERK1/2 (Total ERK) Figure 6 Eect of inhibitors of PKC or MEK on MDR1 induction by TPA. K562 cells were treated with vehicle alone or 32 nM TPA for 16 h, and PD 098059 (100 mM) or staurosporine (1 mM) were added 30 min prior to TPA as indicated. RNA was prepared and MDR1-speci®c or b 2 -microglobulin-speci®c PCR products were ampli®ed and analysed by gel electrophoresis and autoradiography as in Figure 1 202190 at low micromolar concentrations eectively inhibited TPA-induced phosphorylation/activation of p38. Immunoblotting of the same extracts with a phosphorylation-independent p38 antibody indicated that p38 protein levels were unchanged under these conditions ( Figure 7B, lower panel) . The eects of SB 202190 on TPA-induced MDR1 expression were next investigated under similar conditions. K562 cells were treated with vehicle or 32 nM TPA for 16 h, in the absence or presence of 2.5 mM SB 202190 added 30 min prior to TPA, and MDR1 and b 2 -microglobulin mRNA expressions examined. As shown in Figure  7C , TPA-mediated MDR1 induction was completely unaected by inhibition of p38 by SB 202190.
We also examined the possible role of JNK. Figure  7D shows that TPA (32 nM, 30 min) failed to activate JNK, and treatment times up to 16 h and concentrations up to 200 nM were similarly without eect (data not shown). As a positive control, JNK activity was measured in cells subjected to heat shock, and robust JNK activation was observed ( Figure 7D ). These results are consistent with other observations that, in most cell types, JNK is unresponsive to stimulation by TPA but strongly activated by thermal stress (Kyriakis and Avruch, 1996) .
Discussion
Many of the external signals that activate MDR1 gene expression, including serum mitogens and TPA, mediate their eects via MAPKs, and transfection and transformation approaches have demonstrated activation of MDR1 expression by Ras and Raf, upstream components of the MAPK signaling pathway (Cornwell and Smith, 1993; Burt et al., 1988; Chin et al., 1992) . These and other observations, including the presence of a putative AP-1 binding site in the MDR1 promoter/enhancer (Ueda et al., 1987; Chin et al., 1993) , have helped fuel speculation that MDR1 induction by mitogenic signals may occur via MAPK and AP-1 (see reviews by Ignatova and Beck, 1996; Abraham, 1996; Ohkawa et al., 1996) . However, although this is an attractive notion, there has been no direct demonstration in any system that MDR1 induction by mitogens occurs as a consequence of MAPK activation. In this paper, we report the results of a study to directly address this critical question.
Consistent with previous observations, we showed that MDR1 mRNA expression was induced by TPA in K562 cells, and demonstrated that PKC inhibitors, including the PKC-speci®c calphostin C, blocked this Cell lysates were prepared and aliquots (500 mg protein) were subject to JNK immunocomplex assay with GST-cJun as substrate, as described in Materials and methods. An autoradiograph is shown. Molecular mass standards (in kDa) are indicated on the left eect of TPA. We then demonstrated that TPA caused sustained activation of the Raf-1/MEK/ERK cascade via a PKC-dependent pathway. Most signi®cantly, we showed that MDR1 induction by TPA occurred normally in the presence of the MEK inhibitor PD 098059, conditions under which ERK activation was demonstrated to be prevented. These results provide compelling evidence that MDR1 induction by TPA in K562 cells occurs via a PKC-dependent but ERKindependent signal transduction pathway. TPA also activated p38 MAPK, but the failure of SB 202190 to inhibit TPA-mediated MDR1 mRNA expression strongly suggests that p38 is not involved. In addition, the lack of JNK activation by TPA suggests that JNK also is not involved. Therefore, we conclude that MDR1 induction by TPA in K562 cells occurs via a mechanism which is independent of ERK, p38 or JNK signaling pathways.
Based on these ®ndings, an alternative PKCdependent mechanism appears to be responsible. Several mechanisms of PKC-regulated gene expression which bypasses the MAPK cascade have been documented. These include the phosphorylation by PKC of cytosolic anchors proteins which release active factors to the nucleus, translocation of PKC to the nucleus, and activation of nuclear PKC (Buchner, 1995) . We have observed that a signi®cant fraction of cytosolic PKCa rapidly translocates to the nucleus in response to TPA ( Figure 2C ). However, it remains to be determined whether nuclear accumulation of PKCa is required for MDR1 induction. In addition, while PKCa shows the most dramatic changes in subcellular distribution in response to TPA in these cells, our results do not exclude a possible role for less readily detectable TPA-responsive PKC isozymes. TPA stimulates both membrane and nuclear translocation of PKCa, indicating a diversi®cation in TPA-mediated signaling even at the level of a single PKC isoform, thus emphazing the complex nature of the signal transduction pathways potentially involved.
Previous studies demonstrated that a constitutively activated Raf kinase, v-raf, can increase MDR1 promoter activity tenfold, with the responsive sequences localized at nucleotides 769 to 741 relative to the transcription initiation site (Cornwell and Smith, 1993) . Transformation of rat liver epithelial cells with v-raf results in signi®cantly increased mdr1 mRNA expression (Burt et al., 1988) . Because a major consequence of Raf activation is ERK activation, it would be of interest to determine whether ERK activation is required for MDR1 induction by v-raf, particularly in light of the present results. Recent studies have suggested that Raf may have eects in the absence of ERK activation (Daum et al., 1994) , and, consistent with this possibility, additional Raf substrates may exist. For example, the pro-apoptotic protein Bad is a Raf substrate in vitro and possibly also in vivo (Wang et al., 1996) , and Raf kinase has been implicated in regulation of IkB-a phosphorylation (Li and Sedivy, 1993) , although most likely through an indirect mechanism (Janosch et al., 1996) . Interestingly, a recent report suggested that insulin-induced expression of rat mdr1b may be mediated through a signaling pathway involving Raf-1 kinase and NF-kB (Zhou and Kuo, 1997) . Thus, the eects of v-raf on MDR1 gene activation may be due to Raf kinase-mediated signaling events occurring independently of ERK activation. Our results, which exclude ERK but do not necessarily exclude Raf in the mechanism of MDR1 induction, can be reconciled with the previous work if a divergence in signaling downstream of Raf occurs, with one arm activating MEK/ERK and another arm leading to MDR1 induction.
The cis-acting elements and trans-acting factors involved in TPA-mediated MDR expression in K562 cells have been characterized previously (McCoy et al., 1995) . Using synthetic reporter constructs, the TPA responsive sequence was localized to a 769/+20 region of the MDR1 promoter which contained an overlapping consensus binding site for SP1 and EGR transcription factors. Further studies showed that EGR1 binding to this sequence was necessary and sucient to induce reporter gene expression, and that EGR1 expression was rapidly induced by TPA treatment. AP-1 oligonucleotides failed to inhibit complex formation between the 769/+20 probe and nuclear extracts from TPA-treated cells, providing evidence that AP-1 was not involved in MDR1 promoter activation by TPA. Our present ®ndings support the results of McCoy et al. (1995) and indicate that the mechanism of TPA-mediated MDR1 induction does not involve MAPK signaling to AP-1. Although EGR may represent a critical step in the chain of events between PKC activation and MDR1 activation following TPA treatment, the mechanism by which PKC might regulate EGR1 expression or aect its transcriptional activity is currently unknown.
In conclusion, we have shown that MDR1 induction by TPA occurs independently of ERK, p38, or JNK signaling pathways, implicating an alternate mechanism currently under investigation. These ®ndings have broad implication because of the wide spectrum of stimuli known to regulate MDR1 expression. Importantly, MDR1 induction by TPA follows relatively slow kinetics (Figure 1) , in contrast to the rapid initial signaling events. Therefore, the mechanism of induction is likely to involve a series of steps, some timecomsuming in nature. Further investigations of the signaling pathways responsible for MDR1 transcriptional regulation will be important in order to understand how MDR1 gene expression is controlled by mitogenic stimulation and mechanistically linked to oncogenic transformation.
Materials and methods
Materials
Tissue culture media and the SuperScript Preampli®cation System were purchased from GIBCO-BRL Life Technologies (Grand Island, NY, USA). Taq polymerase was from Fisher Scienti®c (Pittsburgh, PA, USA) and T4 polynucleotide kinase from Promega (Madison, WI, USA). Isozyme-specific PKC antibodies were obtained from Transduction Laboratories (Lexington, KY, USA); antibodies to ERK1/2, p38 and Raf-1 kinase were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and antibodies speci®c for the activated, phosphorylated forms of ERK1/2 or p38 were obtained from New England Biolabs (Beverly, MA, USA).
[g- and SB 202190 from Calbiochem (La Jolla, CA, USA). Okadaic acid, staurosporine, H7, calphostin C, TPA, myelin basic protein, protease inhibitors and other chemicals were obtained from Sigma (St. Louis, MO, USA).
Cell Culture
K562 human myelogenous leukemia cells were maintained as suspension cultures at 378C and 95% air/5% CO 2 in RPMI 1640 supplemented with 10% fetal bovine serum. Cells were grown to a density of 10 6 cells/ml and for protein analysis, 10 ml of the cell culture was used for each experimental condition. All compounds added to the cell cultures were prepared as stock solutions in dimethyl sulphoxide (DMSO). The ®nal DMSO concentration was kept constant at 0.1% v/v in both treated and control cell cultures, the latter receiving vehicle alone. Cells treated with calphostin C were subjected to¯uorescent room light for 30 min before transfer to the CO 2 incubator in order to photoactivate the inhibitor, as described previously (Bruns et al., 1991) . The experimental conditions did not aect cell viability as judged by microscopic inspection of the cells and trypan blue exclusion.
RNA extraction and cDNA-PCR analysis of MDR1 expression
Cells were cultivated in 6-well plates with 10 6 cells/2 ml/well and total cellular RNA was extracted by a small-scale procedure using RNA STAT-60 (Tel-Test`B', Inc., Friendswood, TX, USA). cDNA synthesis was carried out using the SuperScript Preampli®cation System as described by the manufacturer. Ampli®cation with primers speci®c for MDR1 or b 2 -microglobulin as a control was performed essentially as described previously (Noonan and Roninson, 1991) with certain modi®cations. Brie¯y, PCR was performed with a Perkin Elmer 2400 Thermocycler and reaction mixtures contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 200 mM of each dNTP, 200 ng of each gene-speci®c primer, 50 ng of RNA-equivalent cDNA, and 1 U of Taq polymerase. Sense primers were 5'-end labeled with g-32 P-ATP for detection of the ampli®ed product by autoradiography. After an initial denaturation at 948C for 5 min, the following step-cycle program was initiated: denaturation at 948C for 30 s, annealing at 528C for 30 s, and extension at 728C for 60 s. For MDR1, 37 cycles were performed, and for b 2 -microglobulin, 27 cycles were performed, each followed by a ®nal extension at 728C for 7 min. Under these conditions, as demonstrated previously (Noonan and Roninson, 1991) and con®rmed in experiments where we varied the amount of input cDNA, the relative yield of PCR product was linear with respect to the amount of MDR1-speci®c or b 2 -microglobulin-speci®c cDNA. PCR products were analysed by 12% acrylamide SDS ± PAGE and autoradiography. Quantitation was performed by subjecting dried gels to phosphorimage analysis.
Subcellular fractionation
Cells were recovered by centrifugation, washed in ice-cold phosphate-buered saline (PBS), and suspended in 0.3 ml of buer A (20 mM Tris/HCl, pH 7.5, 2 mM EDTA, 2 mM EGTA, 10 mM 2-mercaptoethanol, 20 mg/ml aprotinin, 50 mg/ml leupeptin, 10 mM pepstatin, and 1 mM PMSF). Cell suspensions were sonicated with a microprobe, centrifuged (10 min, 1000 g) to remove unbroken cells and nuclear debris, and the homogenate centrifuged (45 min, 100 000 g) to obtain a soluble (cytosolic) fraction and a pellet (particulate fraction) which was suspended in 0.3 ml of buer A. Whole cell extracts were prepared as we described earlier (Osborn and Chambers, 1996) . Nuclear extracts were prepared as follows. K562 cells (2 ± 4610 6 ) were washed in PBS and lysed in 0.5 ml of buer B (10 mM Tris/HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , and 0.5% NP-40, containing protease inhibitors as in buer A above). After 5 min on ice, nuclei were collected by centrifugation (500 g, 10 min), washed once in buer B, repelleted and suspended in 0.15 ml of nuclear lysis buer (20 mM HEPES, pH 7.9, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA). After Dounce homogenization, the suspension was centrifuged (25 000 g, 30 min), and the supernatant dialyzed against 20 mM HEPES, pH 7.9, 0.1 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, plus protease inhibitors.
Immunoblot analysis
Proteins (10 ± 100 mg, as indicated in the ®gure legends) were fractionated by SDS ± PAGE with 8% acrylamide for the analysis of PKC isozymes or Raf-1, and 10% acrylamide for the analysis of ERK or p38. Proteins were transferred to polyvinylidene di¯uoride membrane and probed with antibodies which were used at a dilution of 1 : 1000 except phospho-ERK1/2 which was at 1 : 2500. Primary antibody was detected by horseradish peroxidase-conjugated second antibody (1 : 5000), which was visualized by enhanced chemiluminescence on Hyper®lm (Amersham).
ERK and JNK assays
ERK activity in whole cell extracts was determined by an immunocomplex assay with myelin basic protein as substrate as described (Chen et al., 1994) . Phosphorylated substrate was detected by SDS ± PAGE (12% acrylamide) and autoradiography. JNK activity was determined by an immunocomplex assay with the fusion protein GST-c-Jun (1-79) (Santa Cruz Biotechnology) as substrate as described (Osborn and Chambers, 1996) .
